It’s sad, but true: these days, Europe usually sees new diabetes technology before the U.S. With that in mind, Kelly Close and her team at the highly respected diabetes consultancy Close Concerns have put together a thorough round-up of some of the latest in diabetes technology, specifically regarding patch pumps, from across the pond. What Europe is up to is a taste of what we will see in America soon (hopefully)… Take it away, Kelly!…
Read more »
We recently mentioned a product called DiaPort from Roche, invented way back in 1998, which insulin researchers have been talking about lately as a possible alternative to the implantable insulin pump! Say what? you may ask. What makes this injection port with internal tubing so powerful? Especially when there’s a newer product called iPort that seems to do the same thing, possibly more elegantly?
Well, the DiaPort must be surgically implanted, and its advantage is…
Read more »
By
AmyT on
December 21, 2010
Dr. Josh Makower is Co-founder of Stanford’s Biodesign Innovation Program, and a Consulting Associate Professor of Medicine at the Stanford University Medical School. He’s also Founder and Chief Executive Officer of ExploraMed, a medical device incubator. And he’s a Venture Partner with New Enterprise Associates, where he supports the investing activity in new medical devices.
In short, Dr. Makower is a world authority on med-tech innovation. I bumped into him while beginning preparations for the…
Read more »
By
AmyT on
November 16, 2010
Last Wednesday, diabetes researchers and advocates from around the country convened in Washington, DC, for an FDA hearing on the Artificial Pancreas with the aim of making this pipe dream a reality. The point of the hearing was to allow JDRF and other stakeholders — researchers, industry reps, and patients — a chance to provide input on the Artificial Pancreas Project, in particular “recommendations to ensure the safe and effective testing of artificial pancreas technology…
Read more »
By
AmyT on
November 3, 2010
Why is affordable generic insulin not available to patients in the US? Mainly because the big manufacturers have a stronghold on the patents for this complicated “biologic” drug. But now it seems Big Pharma itself may be presenting a nice alternative.
What I’m talking about is Pfizer’s new attempt to enter the injectable insulin market (less risky than their Exubera flop!) Pfizer and Biocon, a biopharmaceutical company in India, recently announced a multimillion dollar partnership…
Read more »
